← Eichor
Condition: Haic Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Haic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unrese
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT06406634Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Phase 2 · 1 location(s) · Eastern Hepatobiliary Surgery Hospital · NCT07364305Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein T
Phase 2 · 1 location(s) · First Hospital of China Medical University · NCT07483359Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05954897Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2/Phase 3 · 11 location(s) · UNICANCER · NCT06904170Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.
Phase 4 · 1 location(s) · Chen Xiaoping · NCT06311942PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2 · 1 location(s) · West China Hospital · NCT06742424Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcino
Phase 2 · 3 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06208462Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib a
Phase 2 · 1 location(s) · Lei ZHAO · NCT06296563Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2 · 1 location(s) · Tongji Hospital · NCT06192797Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06172205D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Phase N/A · 1 location(s) · Fujian Provincial Hospital · NCT06643208Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904183Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06031285HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectabl
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06244225QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07327788Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients
Phase 2 · 3 location(s) · Fudan University · NCT06812039HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Phase 3 · 1 location(s) · Binkui Li · NCT07594340bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06070636Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside
Phase 2 · 1 location(s) · Erasmus Medical Center · NCT06888063HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic
Phase N/A · 1 location(s) · First Hospital of China Medical University · NCT06632093
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.